Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG01 in advanced solid tumors
NCT05627960Phase 1Recruiting
- Sponsor
- A&G Pharmaceutical, Inc.
- Start
- Feb 2022
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of AG01 in solid tumor, triple negative breast cancer (TNBC), breast cancer and 2 more (5 arms), sponsored by A&G Pharmaceutical, Inc. Primary endpoints: Maximum Tolerated Dose and/or Maximum Administered Dose at 28 days and Overall Response Rate. Started Feb 2022; status: recruiting.
02
Drugs
AG01
03
Conditions
solid tumortriple negative breast cancer (TNBC)breast cancernon-small cell lung cancer (NSCLC)mesothelioma
Beyond the preview
Go deeper on NCT05627960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05627960.